A case of a recurrent hepatic metastasis occurred after curative resection of ascending colon cancer and a hepatic metastasis responding completely to capecitabine plus bevacizumab

• Published in: Gan to kagaku ryoho Vol. 40; no. 12; p. 2014
• Main Authors: Murayama, Minoru, Kohno, Teppei, Miyazawa, Miki, Shimazaki, Asako, Miyaki, Akira, Usuda, Atsuko, Asaka, Shinichi, Yamaguchi, Kentaro, Yokomizo, Hajime, Shiozawa, Shunichi, Yoshimatsu, Kazuhiko, Shimakawa, Takeshi, Katsube, Takao, Naritaka, Yoshihiko
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.11.2013
• Subjects: Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colon, Ascending - surgery; Colonic Neoplasms - drug therapy; Colonic Neoplasms - pathology; Colonic Neoplasms - surgery; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Fluorouracil - administration & dosage; Fluorouracil - analogs & derivatives; Humans; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Male; Recurrence
• ISSN: 0385-0684

Although hepatic resection is the most effective therapy for patients with liver metastasis from colorectal carcinoma, a subset of patients cannot undergo surgical treatment for several reasons, including age-related general health decline or poor conditions associated with coexisting diseases, even if the lesions are resectable. A 75-year-old man with a recurrent lesion in the liver underwent right hemicolectomy and partial hepatic resection to treat colonic cancer and a liver metastasis, followed by uracil and tegafur plus Leucovorin( UFT+LV) as adjuvant chemotherapy at 6 months after the initial surgery. Although the lesion was resectable, the patient preferred chemotherapy to surgery, and capecitabine plus oxaliplatin plus bevacizumab was administered; however, the treatment was stopped in the middle of the second course because of oxaliplatin -related toxicities. Capecitabine plus bevacizumab was introduced as the following chemotherapy regimen, and no adverse reactions were observed during this therapy. After 5 courses of administration, the lesion disappeared on CT examination, and no new lesions were found after 9 courses. Thus, the treatment response was classified as complete response (CR) and remains as such after 13 courses.